500 patients67,039 observations150 daysLIVE

Patient P-03271

Synthetic patientONX-7 · Day 147 · 75+ · F · baseline S19Steering view · 3DOpen companion preview
Therapy response
Declining
Tolerance
Improving
GI state
Unstable
Inflammatory state
Unstable
Nutritional resilience
Unstable
Discontinuation risk
53%

Trajectory

Baseline → today → 30-day prediction · hover a day for signals and events
solid = observed · dashed = predicted
  1. Day 0 ONX-7 startedBaseline state S19
  2. Day 94 Trajectory diverged from predictionObserved response fell below the model's expected path.

What changed?

Trajectory began diverging from predicted response on Day 94.

Primary contributors, last 14 days
  • Toxicity-6
  • Inflammatory activity+3
  • Treatment adherence+2

What helped?

No interventions yet.

    LIFE OS recommendation
    GI Support Protocol GI-04
    59%
    probability of meaningful tolerance improvement
    • 284 similar trajectories
    • 80% showed improvement
    • median effect visible after 8 days

    Daily trackers

    Molecule settings

    The trackers this program marks as important, last 14 days vs the 14 before.

    Energy level
    Daily log
    3.4/10
    worsening · -0.1 vs previous 14 d
    Stress level
    Daily log
    6.8/10
    worsening · +0.3 vs previous 14 d
    Pessimism score
    Daily log
    5.2/10
    worsening · +0.5 vs previous 14 d
    Sleep quality
    Wearable
    34.8/100
    worsening · -3.6 vs previous 14 d
    Libido
    Daily log
    2.9/10
    stable · -0.1 vs previous 14 d
    HRV
    Wearable
    48.4 ms
    worsening · -3.5 vs previous 14 d
    Toxicity
    Blood
    44.3/100
    improving · -4.8 vs previous 14 d
    This trajectory is decaying — what would help, what would not
    Steering view →

    Heading towards failing · 44 from the failing basin, 58 from restoration.

    Would help
    • GI-04 GI Support Protocol
      71% improved among 35 similar · onset 8 d · confidence 59%
    • ME-01 Monitoring Escalation
      100% improved among 11 similar · onset 3 d · confidence 61%
    • DT-01 Dosing / Timing Recommendation
      90% improved among 10 similar · onset 5 d · confidence 61%
    • More protein
      GI -4.7 next day on high-intake days · n 15
    • More caffeine
      GI -2.3 next day on high-intake days · n 20
    Would not help
    • Keep histamine low
      GI +3.1 next day on high-intake days · n 21
    • Keep fat low
      GI +2.8 next day on high-intake days · n 21
    State influencers · digestive

    Next-day GI change on high-intake vs low-intake days, last 60 days. Attribution from this patient's own log; sensitivity set by their biology.

    • Protein
      -4.7supporter · 95%
    • Histamine load
      +3.1detractor · 88%
    • Dietary fat load
      +2.8detractor · 74%
    • Caffeine
      -2.3supporter · 56%
    • Alcohol
      +0.9no signal · 21%
    • Lactose
      -0.1no signal · 15%

    Biological layers

    Which pathways look influenced, and by which layer of this person's biology.

    Pathways under pressure
    • Butyrate / short-chain fatty acid production 55
      • MicrobiomeButyrate capacity 42/100
      • Daily logFibre intake low in recent food logs
    • Drug metabolism and exposure 55
      • DNADPYD *2A → slower clearance
      • BloodToxicity index 44
    • Mucosal barrier integrity 50
      • DNAFUT2 non-secretor lowers mucosal fucosylation
      • Daily logGI symptom score 60 and rising
    • Inflammatory signalling 50
      • DNAIL6 -174 variant raises baseline inflammatory tone
      • BloodInflammatory load index 60
    • Autonomic recovery 25
      • WearableResting HR 73 bpm
    DNA
    Fictional pharmacogenomic panel
    • FUT2 rs601338 AA (non-secretor)
      Reduced mucosal fucosylation
    • IL6 -174 G/C
      Higher inflammatory tone
    • DPYD *2A heterozygous
      Slower drug clearance
    • CYP2D6 Intermediate metabolizer
      Expected exposure
    • MTHFR C677T
      Reduced folate turnover
    Microbiome
    Shannon diversity 2.1 · butyrate capacity 42/100
    • Akkermansia muciniphilaNormal
    • Faecalibacterium prausnitziiNormal
    • Bacteroides fragilisNormal
    • Bifidobacterium longumNormal
    • EnterobacteriaceaeNormal
    Wearable, last 14 days
    daily evolution fed into the runtime
    HRV
    47 ms
    Sleep
    6.1 h
    Steps
    4,100
    Resting HR
    75 bpm
    Daily log: GI score 60, nutritional resilience 35, adherence 69.

    What this patient sees in NostraAI

    The content that steers the trajectory: what to eat, what to do, what to take.

    Open companion preview
    What to eat
    • Prepare a plain, low-fat pasta or rice meal and note how it feels afterwards
    • Choose a freshly cooked, lean protein; avoid frying, rich sauces and leftovers for now
    • Add one soluble-fibre source (oats, cooked carrots, banana) to breakfast
    • Avoid known triggers for now: fried or oily food, dairy, alcohol
    What to do
    • Track each bowel movement today: time, stool form, urgency, overnight waking
    • A 15-minute walk after lunch
    • Keep the sleep window steady
    • Keep hydration steady: small amounts through the day rather than large volumes at once
    What to take
    • Take the scheduled dose as agreed with your care team
    • Electrolyte solution, one sachet after any loose stool
    • Fictional demo item: oral nutrition supplement with lunch

    284 biologically similar trajectories

    Black: this patient. Green: similar patients whose intervention worked. Orange: similar patients where it did not.

    PatientSimilarityBaselineInterventionOutcomeResponse today
    P-0313719%S0288
    P-0304319%S1687
    P-0300719%S0985
    P-0317619%S1485
    P-0305619%S0584
    P-0314220%S1584
    P-0308720%S0483
    P-0304219%S1583
    P-0332919%S1883
    P-0332419%S1482
    P-0305419%S0382
    P-0344619%S0381